Kiora Pharmaceuticals (KPRX) Enterprise Value (2016 - 2025)
Kiora Pharmaceuticals (KPRX) has disclosed Enterprise Value for 11 consecutive years, with -$1.0 million as the latest value for Q2 2025.
- For the quarter ending Q2 2025, Enterprise Value rose 84.8% year-over-year to -$1.0 million, compared with a TTM value of -$1.0 million through Jun 2025, up 84.8%, and an annual FY2024 reading of -$26.8 million, down 989.57% over the prior year.
- Enterprise Value was -$1.0 million for Q2 2025 at Kiora Pharmaceuticals, up from -$20.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1.0 million in Q2 2025 and bottomed at -$31.3 million in Q1 2024.
- Average Enterprise Value over 5 years is -$10.4 million, with a median of -$6.6 million recorded in 2024.
- The sharpest move saw Enterprise Value plummeted 989.57% in 2024, then skyrocketed 84.8% in 2025.
- Year by year, Enterprise Value stood at -$7.9 million in 2021, then skyrocketed by 38.6% to -$4.9 million in 2022, then surged by 49.31% to -$2.5 million in 2023, then tumbled by 989.57% to -$26.8 million in 2024, then soared by 96.27% to -$1.0 million in 2025.
- Business Quant data shows Enterprise Value for KPRX at -$1.0 million in Q2 2025, -$20.3 million in Q1 2025, and -$26.8 million in Q4 2024.